Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review

BACKGROUND: Tocilizumab is a monoclonal antibody that interrupts interleukin-6 signalling, reducing downstream effects on inflammation and the innate immune response. It was shown to reduce mortality in patients with severe or critical coronavirus disease 2019 (COVID-19). Pregnant and breastfeeding...

Descripción completa

Detalles Bibliográficos
Autores principales: Jorgensen, Sarah C.J., Lapinsky, Stephen E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Narrative Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381634/
https://www.ncbi.nlm.nih.gov/pubmed/34438068
http://dx.doi.org/10.1016/j.cmi.2021.08.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381634/
https://www.ncbi.nlm.nih.gov/pubmed/34438068
http://dx.doi.org/10.1016/j.cmi.2021.08.016

Ejemplares similares